𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chromosome banding anomalies in acute myeloid leukaemia

✍ Scribed by Tamás Fleischmann; Ferenc Bodor

Publisher
John Wiley and Sons
Year
1975
Tongue
French
Weight
290 KB
Volume
15
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Chromosome analysis in two cases of acute myeloid leukaemia are reported. On the basis of slight aberrations in the banding pattern marker chromosomes were observed in both cases. In one case a widened C‐band of an additional D chromosome, and in the other case an unusual negative fluorescent band below the centromere of one of the chromosomes 16, were seen.

📜 SIMILAR VOLUMES

TdT expression in acute myeloid leukaemi
TdT expression in acute myeloid leukaemia
✍ Stark, A. N. ;MacKarill, I. D. ;Limbert, H. J. ;Evans, P. ;Scott, C. S. 📂 Article 📅 1988 🏛 Springer-Verlag ⚖ 486 KB

A total of 412 cases of acute leukaemia were examined for the presence of nuclear terminal deoxynucleotidyl transferase (TdT) by indirect immunofluorescence. Of the 129 cases of acute myeloblastic leukaemia (AML FAB groups M1/M2) examined, 18% (n = 23) had significant proportions (greater than 10%)

Non-random chromosome changes in acute m
Non-random chromosome changes in acute myeloid leukemia. Chromosome banding examination of 30 cases at diagnosis
✍ F. Mitelman; P. G. Nilsson; G. Levan; L. Brandt 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 French ⚖ 651 KB

## Abstract Bone‐marrow chromosomes were examined with the G‐banding technique in 30 patients with acute myeloid leukemia at the time of diagnosis. In 13 of the 30 patients (43%) only normal diploid bone‐marrow cells were found, and no deviations from the normal banding pattern could be detected in

Relevance of clinical trials in acute my
Relevance of clinical trials in acute myeloid leukaemia
✍ Apostolia M. Tsimberidou; Elihu Estey 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

## Abstract Patients with newly diagnosed acute myeloid leukaemia (AML) are increasingly being enrolled in clinical trials sponsored by pharmaceutical companies or the National Cancer Institute. These trials routinely exclude patients who are less likely to respond (LLTR), e.g. those with Zubrod pe